GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » Total Payout Ratio

Y-Biologics (XKRX:338840) Total Payout Ratio : 0.01 (As of May. 18, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Y-Biologics Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Y-Biologics's current Total Payout Ratio is 0.01.


Y-Biologics Total Payout Ratio Historical Data

The historical data trend for Y-Biologics's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-Biologics Total Payout Ratio Chart

Y-Biologics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Payout Ratio
Get a 7-Day Free Trial 2.01 0.04 - 0.67 0.03

Y-Biologics Quarterly Data
Dec17 Dec18 Dec19 Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.04 - - -

Competitive Comparison of Y-Biologics's Total Payout Ratio

For the Biotechnology subindustry, Y-Biologics's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Y-Biologics's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Y-Biologics's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Y-Biologics's Total Payout Ratio falls into.


;
;

Y-Biologics Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Y-Biologics's Total Payout Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 201.228 + 0) / -6441.69
=0.03

Y-Biologics's Total Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -1824.391
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Y-Biologics Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Y-Biologics's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Y-Biologics Business Description

Traded in Other Exchanges
N/A
Address
B715 Daedeok Biz Center, 17 Techno 4-ro, Yuseong-gu, Daejeon, KOR, 34013
Y-Biologics Inc is a company that has a variety of development candidate antibodies based on Korea's highest-level antibody discovery platform technology and then independently develops antibody treatments or jointly develops cutting-edge biopharmaceuticals by fusing them with partner's platform technology. Its main business model is based on a globally competitive antibody discovery platform and consists of the development of new bio drug candidates and early technology transfer, and contract research services that generate stable cash flow.

Y-Biologics Headlines

No Headlines